Lv1
20 积分 2026-05-18 加入
Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial
3小时前
已关闭
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial
1个月前
已完结
Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma
2个月前
已完结
B cell immunometabolism in health and disease
2个月前
已完结
Leveraging immunologically based therapies to treat diffuse large B-cell lymphoma
2个月前
已完结
Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia
3个月前
已完结
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
3个月前
已完结
Novel treatment strategies for chronic myeloid leukemia
3个月前
已完结
Chronic Myeloid Leukemia
3个月前
已完结
Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia
3个月前
已完结
皖公网安备34019202002308
